ArticleDrugs & aging2026
Effectiveness of Sacubitril/Valsartan in Reducing Hospitalizations in Older Belgian Adults with Heart Failure and Reduced Ejection Fraction: An Age-Stratified Study.
Article in Drugs & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Patterns of Evidence-Based Medication Use in Older Adults with Chronic Heart Failure in Slovakia: A Population-Based Study Using the National Health Information Center Database.Drugs & aging · 2026Article
- Dose optimization of sacubitril/valsartan in Chinese chronic heart failure patients: integration of physiologically based pharmacokinetic modeling and real-world data.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure with reduced ejection fraction is increasingly prevalent in older adults, yet data on guideline-directed therapies in the oldest age groups remain limited.
objectiveTo assess outcomes of sacubitril/valsartan in adults aged ≥75 years, across age strata (≥75, ≥80, ≥85, ≥90 years; 75-79, 80-84, 85- 89 years), focusing on cardiovascular, heart failure, and all-cause hospitalizations, and mortality.
methodsThis retrospective study evaluated all patients aged ≥ 75 years in Belgium with chronic heart failure with reduced ejection fraction who started sacubitril/valsartan between 1 November, 2016 and 31 December, 2018.
resultsA total of 1705 patients were divided into the following age groups: 75-79, 80-84, 85-89, and ≥ 90 years. Cardiovascular hospitalization rates significantly decreased across all age groups after sacubitril/valsartan initiation. Patients aged 75-79 years showed a reduction from 0.74 events/year (95% confidence interval [CI] 0.68-0.81) prior to treatment to 0.54 (95% CI 0.47-0.62, p < 0.001) after initiation. Rates fell from 0.73 (95% CI 0.66-0.80) to 0.53 (95% CI 0.44-0.65, p < 0.001) in those aged 80-84 years, from 0.62 (95% CI 0.52-0.74) to 0.44 (95% CI 0.35-0.57, p < 0.01) in those aged 85-89 years, and from 0.78 (95% CI 0.59-1.03) to 0.42 (95% CI 0.22-0.83, p < 0.01) in patients aged ≥ 90 years. Heart failure-related hospitalization rates also showed consistent reductions: 0.34 (95% CI 0.30-0.39) prior to treatment to 0.28 (95% CI 0.22-0.34) after initiation in patients aged 75-79 years, and from 0.38 (95% CI 0.33-0.43) to 0.30 (95% CI 0.23-0.39) in those aged 80-84 years (all p < 0.05). The rates decreased from 0.35 (95% CI 0.28-0.44) to 0.27 (95% CI 0.20-0.38, p = 0.08) in those aged 85-89 years and from 0.52 (95% CI 0.36-0.76) to 0.29 (95% CI 0.12-0.75, p < 0.05) in the oldest patients aged ≥ 90 years.
conclusionsBroader application of guideline-directed medical therapy in geriatric heart failure with reduced ejection fraction care should be prioritized.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.